California Institute for Regenerative Medicine   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2004)

Organization Overview

First Clinical Trial
2012
NCT01458405
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

California Institute for Regenerative Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Anemia, Sickle Cell (Phase 1)

Bone Diseases, Metabolic (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Familial Primary Pulmonary Hypertension (Phase 1)

Granuloma (Phase 2)

Granulomatous Disease, Chronic (Phase 2)

Hemoglobinopathies (Phase 1)

Hypertension (Phase 1)

Immunologic Deficiency Syndromes (Phase 2)

Infarction (Phase 2)

Motor Neuron Disease (Phase 3)

Myocardial Infarction (Phase 2)

Neoplasms (Phase 1)

Osteonecrosis (Phase 1)

Osteoporosis (Phase 1)

Sarcoma (Phase 1)

Sclerosis (Phase 1)

Severe Combined Immunodeficiency (Phase 2)

Thalassemia (Phase 1)

Ventricular Dysfunction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 28